Mizuho Said Adaptimmune Therapeutics plc (ADAP) ASCO Data 'Incrementally Supportive'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
Go back to Mizuho Said Adaptimmune Therapeutics plc (ADAP) ASCO Data 'Incrementally Supportive'
June 2, 2020 5:52 AM EDT
Adaptimmune Therapeutics plc (NASDAQ: ADAP) today announced the pricing of an underwritten public offering of 20,500,000 of its American Depositary Shares (ADSs) at a price to the public of $11.00 per ADS. In connection with the offering, Adaptimmune has granted the underwriters a 30-day option to purchase... More
June 1, 2020 6:12 AM EDT
Adaptimmune Therapeutics plc (NASDAQ: ADAP) today announced that it intends to offer and sell 12,500,000 American Depositary Shares (ADSs) in an underwritten public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the... More
May 29, 2020 7:33 AM EDT
Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in cell therapy to treat cancer, presented updated data from its ADP-A2M4 Phase 1 trial at the American Society for Clinical Oncology (ASCO) Annual Meeting. The data demonstrate durability and responses in synovial sarcoma, supporting SPEARHEAD-1 as a potential registrational trial. The ASCO presentation also describes a new response in a patient with lung cancer, and a response in a patient with head and neck cancer (reported in January).
The Company also announced new responses in the SURPASS trial, confirming the potential for... More
